ILMN250117C113000
- 0.00
- 0.000.00%
Illumina Newsroom
BofA Securities Maintains Illumina(ILMN.US) With Sell Rating, Maintains Target Price $120
Bernstein Maintains Illumina(ILMN.US) With Hold Rating
Sector Update: Health Care Stocks Fall Tuesday Afternoon
Express News | Illumina Shares Reverse Premarket Losses, Now up 2.5%
Illumina, Nvidia Collaborate to Decode Biology and Propel Precision Health
Illumina Announces Preliminary Financials For Q4 2024 With $1.10B Revenue, 2024 Revenue At $4.33B, GAAP EPS $5.65-$5.67; Non-GAAP EPS $4.12-$4.14; Sees 2025 Revenue Outlook Of $4.28B-$4.4B, Non-GAAP Margin 23%, EPS Growth 10%
Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?
Express News | Illumina Shares Fall 3.6% Premarket After Prelim Q4 Results
Express News | Illumina Inc Q4 Shr View $0.91, Rev View $1.07 Bln -- LSEG IBES Data
Illumina Sees 4Q Rev $1.1B >ILMN
Illumina Sees 4Q EPS 77c-EPS 79c >ILMN
Express News | Illumina: For FY 2025, Expect Constant Currency Revenue Growth in Low Single Digits (Reported Revenue in Range of About $4.28 Bln to $4.4 Bln)
Express News | Illumina Inc: Preliminary Non-Gaap Diluted EPS of Approximately $0.91 - $0.93 for Q4 2024
Express News | Illumina Q4 Revenue USD 1,100 Million Vs. IBES Estimate USD 1,072 Million
Express News | Illumina Outlook FY Adjusted Operating Margin 23%
Express News | Illumina Q4 EBIT Margin 16.7%
Express News | Illumina Q4 Adjusted EBIT Margin 1.5%
Press Release: Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025
Because Mina has launched a pilot proteomics project in collaboration with biobanks and biopharmaceutical partners in the United Kingdom.
The research will generate key reference datasets using Illumina Protein Prep solutions. San Diego, California, USA, January 14, 2025 /PR Newswire/ -- The global leader in Gene Sequencing and microarray technology, Illumina (Nasdaq: ILMN), announced a collaboration with deCODE Genetics, Standard BioTools, Tecan, GlaxoSmithKline, Johnson & Johnson, and Novartis to launch a pilot proteomics project analyzing samples from the UK Biobank.
Because Minna is collaborating with NVIDIA to decode biology and promote the development of precision health.
The collaboration between the two parties will combine Genomics sequencing technology and Illumina Connected Software solutions with NVIDIA tools to jointly develop biological foundational models. San Diego, California, January 14, 2025 /PR Newswire/ -- The global leader in Gene Sequencing and chip technology, Illumina (Nasdaq: ILMN), announced a partnership with NVIDIA to advance the development of multi-omics data analysis and interpretation technology platforms, accelerating the progress of clinical research, genomics AI development, and drug discovery. In order to optimize the massive amounts of data involved in multi-omics research.